mXELIRI+BV could be an alternative to FOLFIRI as a standard second line backbone treatment for mCRC.doi:10.1093/annonc/mdz338.113Hiroshi MatsuokaYoshinori KagawaMitsuyoshi OtaAkitaka MakiyamaKohei AkiyoshiTadamichi DendaChu MatsudaYasuhide Yamada
FOLFIRI化疗方案联合贝伐单抗治疗转移性结直肠癌的临床观察
We retrospectively investigated the safety and efficacy on outpatient chemotherapy including bevacizumab(BV)as secondline therapy for inoperable metastatic colorectal cancer. Analytical subjects were thirty patients treated with chemotherapy including BV as second-line therapy after first disease progression. All...
Methods: This phase III study randomized pts with measurable mCRC treated in first-line with BV plus fluoropyrimidine, FOLFIRI, FOLFOX or FOLFOXIRI, to receive in second-line mFOLFOX6 or FOLFIRI (depending on first-line CT) with or... G Masi,F Loupakis,L Salvatore,... - 《Journal of ...
Q:LOMS0?GfOl9BdfXX2m?KLz3CvYQ8vggtyo;d7Yx:bsO4Qm2FdJVCy90Zy2wzEeWO6qRYB4vzjQJit54556Sq:9vS5aLtRuq6CMlA:7ooHetqYIYYG_37V62mt7XkRwqEj_?245ki9gbrIdT5z=;baA_mykWPNLRppS0q8PpYJjxPK1Ttvo7OJ_Wzc5:AUrIJLrdFddORHa2A;okZ4ntC:mZCE2:LayUn=Bv36dIuYk3|obVINWCL5|cw3zxxM7IMA61...
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts). Eur J Cancer Suppl 2009; 7: 357.Loupakis F, Ruzzo A, Salvatore L, et al. VEGF gene polymorphisms in the prediction of benefit from ...
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC) J Clin Oncol, 34 (Suppl. 4) (2016) Abstr 493 Google Scholar 18. K. Muro, N. Boku, Y...
CONCLUSIONS: The results of this study suggest that FOLFIRI plus BV is a viable option in second-line treatment for mCRC refractory to first-line FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) alone, and indicate that CA125 might be a predictive biomarker for the outcome....
The frequencies of adverse events related BV, such as bleeding, thrombosis, and gastrointestinal perforation, were within the ranges of previous reports. However, there were no treatment-related deaths. The combination of bevacizumab plus FOLFIRI or FOLFOX showed modest activity and was relatively ...
Retrospective data suggested that the continuation of BV with second-line CT beyond progression (PD) in pts who received BV in first-line can improve the outcome. Recently, results of the AIO/AMG ML18147 study demonstrated an improved ov... G Masi,F Loupakis,L Salvatore,... - 《Journal ...